
First published in the Government *Gazette*, Electronic Edition, on 30th April 2015 at 5:00 pm.

No. S 253

MISUSE OF DRUGS ACT (CHAPTER 185)

MISUSE OF DRUGS (AMENDMENT) REGULATIONS 2015

In exercise of the powers conferred by section 58 of the Misuse of Drugs Act, the Minister for Home Affairs makes the following Regulations:

Citation and commencement

1. These Regulations may be cited as the Misuse of Drugs (Amendment) Regulations 2015 and come into operation on 1 May 2015.

Amendment of Fourth Schedule

2. The Fourth Schedule to the Misuse of Drugs Regulations (Rg 1) is amended —

(a) by deleting paragraph 1 and substituting the following paragraph:

“1. The following substances and products, namely:

- (1) 1-Benzylpiperazine (also known as BZP)
- (2) 4-Bromo-2,5-dimethoxy- α -methylphenethylamine (also known as Brolamfetamine or DOB)
- (3) 4-Bromo-2,5-dimethoxyphenethylamine (also known as 2C-B)
- (4) Bufotenine
- (5) Cannabinol
- (6) Cannabinol derivatives
- (7) Cannabis and cannabis resin
- (8) Cathinone

-
-
- (9) Coca leaf
 - (10) Concentrate of poppy-straw
 - (11) N,N-Diethyltryptamine
 - (12) 2,5-Dimethoxy-4, α -dimethylphenethylamine
 - (13) 2,5-Dimethoxy- α -methylphenethylamine
 - (14) N, α -Dimethyl-3,4-(methylenedioxy)phenethylamine (also known as MDMA)
 - (15) 3-(1,2-Dimethylheptyl)-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran
 - (16) N,N-Dimethyltryptamine
 - (17) 4-Ethyl-2,5-dimethoxy- α -methylphenethylamine
 - (18) N-Ethyl- α -methyl-3,4-(methylenedioxy)phenethylamine (also known as MDEA)
 - (19) Eticyclidine
 - (20) Etryptamine
 - (21) 1-Hydroxy-3-pentyl-6a,7,10,10a-tetrahydro-6,6,9-trimethyl-6-H-dibenzo[b,d]pyran
 - (22) Lysergamide
 - (23) Lysergide and other *N*-alkyl derivatives of lysergamide
 - (24) Mescaline
 - (25) 3-Methoxy- α -methyl-4,5-(methylenedioxy)phenethylamine
 - (26) *p*-Methoxy- α -methylphenethylamine
 - (27) N-Methyl- α -ethyl-3,4-(methylenedioxy)phenethylamine (also known as MBDB)
 - (28) N-[α -Methyl-3,4-(methylenedioxy)phenethyl]hydroxylamine
 - (29) α -Methyl-3,4-(methylenedioxy)phenethylamine (also known as Tenamfetamine or MDA)
 - (30) 4-Methylaminorex
 - (31) Psilocin
 - (32) Psilocybine
 - (33) Rolicyclidine

-
-
- (34) Tenocyclidine
- (35) 1-(3-Trifluoromethylphenyl)piperazine (also known as TFMPP)
- (36) 3,4,5-Trimethoxy- α -methylphenethylamine”;
- (b) by deleting “Bk-MDDMA” in item (1) of paragraph 15 and substituting “bk-MDDMA”;
- (c) by inserting, immediately after item (8) of paragraph 15, the following items:
- “(8A) 1-(4-Bromophenyl)-2-(methylamino)propan-1-one (also known as 4-Bromomethcathinone or Brephedrone or 4-BMC)
- (8B) 1-(4-Chlorophenyl)-2-(methylamino)propan-1-one (also known as 4-Chloromethcathinone or Clephedrone or 4-CMC)”;
- (d) by deleting items (10) and (11) of paragraph 15 and substituting the following items:
- “(10) 1-(3,4-Dimethylphenyl)-2-(methylamino)propan-1-one (also known as 3,4-Dimethylmethcathinone or 3,4-DMMC)
- (10A) 2-(Ethylamino)-1-(4-fluorophenyl)propan-1-one (also known as 4-Fluoroethcathinone or 4-FEC)
- (11) 2-(Ethylamino)-1-(4-methylphenyl)propan-1-one (also known as 4-Methylethcathinone or 4-MEC)”;
- (e) by deleting items (15) and (16) of paragraph 15 and substituting the following items:
- “(14A) 1-(4-Ethylphenyl)-2-(methylamino)propan-1-one (also known as 4-Ethylmethcathinone or 4-EMC)
- (15) 1-(4-Fluorophenyl)-2-(methylamino)propan-1-one (also known as 4-Fluoromethcathinone or Flephedrone or 4-FMC)
- (15A) 1-(4-Fluorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one (also known as 4-Fluoro- α -PVP)

(16) 1-(4-Methoxyphenyl)-2-(methylamino)propan-1-one (also known as 4-Methoxymethcathinone or Methedrone or bk-PMMA or PMMC)”;

(f) by deleting item (21) of paragraph 15 and substituting the following item:

“(21) 1-(4-Methylphenyl)-2-(methylamino)propan-1-one (also known as 4-Methylmethcathinone or Mephedrone or 4-MMC)”;

(g) by deleting item (1) of paragraph 17 and substituting the following items:

“(1) N-(1-Adamantyl)-5-fluoropentyl-1H-indazole-3-carboxamide (also known as 5-Fluoro-APINACA or 5F-AKB48) and its fluoro positional isomers in the pentyl group

(1A) N-(1-Adamantyl)-5-fluoropentyl-1H-indole-3-carboxamide (also known as 5-Fluoro-APICA or STS-135) and its fluoro positional isomers in the pentyl group

(1B) N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide (also known as APINACA)”;

(h) by inserting, immediately after item (2) of paragraph 17, the following items:

“(2A) N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (also known as AB-FUBINACA) and its fluoro positional isomers in the phenyl ring

(2B) 4-(2-Aminopropyl)benzofuran (also known as 4-APB)”;

(i) by inserting, immediately after item (4) of paragraph 17, the following items:

“(4A) 7-(2-Aminopropyl)benzofuran (also known as 7-APB)

(4B) 4-(2-Aminopropyl)-2,3-dihydrobenzofuran (also known as 4-APDB)”;

(j) by inserting, immediately after item (6) of paragraph 17, the following items:

“(6A) 7-(2-Aminopropyl)-2,3-dihydrobenzofuran (also known as 7-APDB)

(6B) 2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (also known as 25B-NBOMe)”;

(k) by inserting, immediately after item (8) of paragraph 17, the following item:

“(8A) 2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (also known as 25C-NBOMe)”;

(l) by inserting, immediately after item (10) of paragraph 17, the following item:

“(10A) 3,4-Dichloro-N-{[1-(dimethylamino)cyclohexyl]methyl}benzamide (also known as AH-7921) and its dichloro positional isomers in the phenyl ring”;

(m) by inserting, immediately after item (15) of paragraph 17, the following item:

“(15A) 2-(2,5-Dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (also known as 25H-NBOMe)”;

(n) by deleting items (20), (21) and (22) of paragraph 17 and substituting the following items:

“(20) [1-(5-Fluoropent-1-yl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (also known as XLR-11 or 5-Fluoro-UR-144) and its fluoro positional isomers in the pentyl group

(21) 1-(4-Fluorophenyl)piperazine (also known as 4-Fluorophenylpiperazine or 4-FPP) and its fluoro positional isomers in the phenyl ring

(22) 1-(4-Fluorophenyl)propan-2-amine (also known as 4-Fluoroamphetamine or 4-FA) and its fluoro positional isomers in the phenyl ring”;

(o) by inserting, immediately after item (27) of paragraph 17, the following item:

“(27A) 2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (also known as 25I-NBOMe)”;

(p) by deleting items (29), (30) and (31) of paragraph 17 and substituting the following items:

“(29) N-Methyl-1-(4-fluorophenyl)propan-2-amine (also known as 4-Fluoromethamphetamine or 4-FMA) and its fluoro positional isomers in the phenyl ring

(30) N-Methyl-1-(4-methoxyphenyl)propan-2-amine (also known as 4-Methoxymethamphetamine or para-Methoxymethamphetamine or PMMA) and its methoxy positional isomers in the phenyl ring

(31) N-Methyl-1-(4-methylphenyl)propan-2-amine (also known as 4-Methylmethamphetamine or 4-MMA) and its methyl positional isomers in the phenyl ring”;

(q) by inserting, immediately after item (38) of paragraph 17, the following items:

“(38A) Quinolin-8-yl 1-(cyclohexylmethyl)-1H-indole-3-carboxylate (also known as BB-22 or QUCHIC)

(38B) Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (also known as 5-Fluoro-PB-22 or 5-Fluoro-QUPIC) and its fluoro positional isomers in the pentyl group

(38C) Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (also known as PB-22 or QUPIC)”.

[G.N. Nos. S 390/99; S 231/2000; S 436/2000; S 140/2001; S 492/2001; S 506/2005; S 490/2006; S 108/2007; S 525/2010; S 684/2010; S 270/2013; S 322/2014; S 571/2014]

Made on 30 April 2015.

LEO YIP
*Permanent Secretary,
Ministry of Home Affairs,
Singapore.*

[MHA 112/2/0049; AG/LEGIS/SL/185/2015/2 Vol. 1]